{"id":66053,"date":"2023-09-27T12:27:05","date_gmt":"2023-09-27T16:27:05","guid":{"rendered":"https:\/\/ifintechworld.com\/markets\/which-is-a-better-pick-keurig-dr-pepper-stock-or-zoetis\/"},"modified":"2023-09-27T12:27:07","modified_gmt":"2023-09-27T16:27:07","slug":"which-is-a-better-pick-keurig-dr-pepper-stock-or-zoetis","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=66053","title":{"rendered":"Which Is A Better Pick \u2013 Keurig Dr Pepper Stock Or Zoetis?"},"content":{"rendered":"
\n

We believe that Zoetis stock <\/strong>(NYSE: ZTS), an animal health company, is a better pick than Keurig Dr Pepper stock<\/strong> <\/strong>(NASDAQ
\n NDAQ
\n <\/fbs-ticker>: KDP), given its better prospects. Although these companies are from different sectors, we compare them because they have a similar operating income of around $3 billion. The decision to invest often comes down to finding the best stocks within the parameters of certain characteristics that suit an investment style. The size of profits can matter, as larger profits can imply greater market power. Since these stocks are from different sectors, comparing P\/S against one another may not be helpful. We compare their current multiples with the historical ones in the sections below to better gauge their valuations.<\/p>\n

Interestingly, Zoetis
\n ZTS
\n <\/fbs-ticker> has had a Sharpe Ratio of 0.9<\/strong> since early 2017, while the figure stood at -0.1<\/strong> for Keurig Dr Pepper and 0.6<\/strong> for the S&P 500 Index over the same period. This compares with the Sharpe of 1.3<\/strong> for the Trefis Reinforced Value portfolio. Sharpe is a measure of return per unit of risk, and high-performance portfolios can provide the best of both worlds.<\/p>\n

Looking at stock returns, ZTS has fared much better, with 21% gains this year compared to a 9% decline for KDP stock and a 13% rise in the broader S&P500 index. There is more to the comparison, and in the sections below, we discuss why we believe ZTS will offer better returns over KDP in the next three years. We compare a slew of factors, such as historical revenue growth, returns, and valuation, in this analysis.<\/p>\n

1. Zoetis\u2019 Revenue Growth Is Slightly Better<\/strong><\/p>\n